semaglutide decreases cardiovasc events in nondiabetics
A new study found that patients with pre-existing cardiovascular disease who were overweight or obese but did not have diabetes still had significantly better cardiovascular outcomes with semaglutide, in the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT trial): cardiovasc better with semaglutide without diabetes NEJM2023 in dropbox, or DOI: 10.1056/NEJMoa2307563 Details : -- 17,604 patients who had a BMI of at least 27 with a history of cardiovascular disease but no history of diabetes were enrolled in this multicenter, double-blind, drug company-sponsored randomized controlled, event-driven superiority trial -- patients were recruited in 41 countries, were at least 45 years old, but did not have NYHA class IV heart failure, or end-stage renal disease/dialysis -- mean age 62, 72% male, 84% white/8% Asian/4% Black/10% Latinx -- BMI 33 (72% had BMI>30), waist...